Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.33 |
| ▸ | CPB1 | P15086 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22093251 | 0.88 | DGAT1 (0.34) | DGAT1CPB2CPB1 | |
| SCHEMBL2473549 | 0.87 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL5764924 | 0.83 | KDM4E (0.35) | DGAT1CPB2CPB1 | |
| SCHEMBL22093263 | 0.83 | CPB1 (0.33) | DGAT1CPB2CPB1CYP2C9TSHR | |
| SCHEMBL31631922 | 0.82 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL3637180 | 0.78 | CPB2 (0.36) | DGAT1CPB2CPB1 | |
| SCHEMBL18431180 | 0.78 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL2822834 | 0.78 | DGAT1 (0.38) | DGAT1CYP2C9CYP2C19 | |
| SCHEMBL2074286 | 0.77 | DUT (0.35) | DGAT1 | |
| SCHEMBL26693973 | 0.77 | DGAT1 (0.35) | DGAT1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | DGAT1 1457/4885CPB2 234/4885CPB1 168/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | DGAT1 1870/4885CPB2 167/4885CPB1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.